# Study Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women

> **NCT02937766** · PHASE3 · TERMINATED · sponsor: **AMAG Pharmaceuticals, Inc.** · enrollment: 60 (actual)

## Conditions studied

- Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) in Healthy Post-menopausal Women

## Interventions

- **DRUG:** Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)
- **DRUG:** Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)

## Key facts

- **NCT ID:** NCT02937766
- **Lead sponsor:** AMAG Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-10-07
- **Primary completion:** 2017-01-06
- **Final completion:** 2017-03-27
- **Target enrollment:** 60 (ACTUAL)
- **Why stopped:** The Sponsor elected to discontinue the study prematurely due to business reasons
- **Last updated:** 2022-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02937766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02937766, "Study Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT02937766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*